Under the terms of the agreement, Eczacibasi Ilac Pazarlama (EIP) will purchase the product from Pharming and market, sell and distribute it in Turkey. EIP will also pay a license fee to Pharming for the product. The agreement covers the use of Rhucin to treat acute attacks of hereditary angioedema with a right of first refusal to EIP for other indications. EIP will be responsible for registration of the product in Turkey and has already taken the first steps in this process.
The current agreement is part of Pharming’s strategy to make Rhucin available to patients worldwide while, at the same time, building a clinical database supporting registration procedures in the EU and the US.